Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Total Current Liabilities for 9 consecutive years, with $90.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 3.51% to $90.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $90.1 million, a 3.51% increase, with the full-year FY2024 number at $102.2 million, up 31.07% from a year prior.
  • Total Current Liabilities was $90.1 million for Q3 2025 at Denali Therapeutics, down from $91.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $391.1 million in Q1 2023 to a low of $51.4 million in Q2 2021.
  • A 5-year average of $167.5 million and a median of $90.1 million in 2025 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 577.2% in 2022, then crashed 80.26% in 2023.
  • Denali Therapeutics' Total Current Liabilities stood at $378.2 million in 2021, then dropped by 3.79% to $363.9 million in 2022, then tumbled by 78.57% to $78.0 million in 2023, then skyrocketed by 31.07% to $102.2 million in 2024, then dropped by 11.8% to $90.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Total Current Liabilities are $90.1 million (Q3 2025), $91.1 million (Q2 2025), and $91.9 million (Q1 2025).